A randomized, placebo-controlled trial (NCIC CTG MAPI) examining the effects of letrozole on mammographie breast density and other end organs in postmenopausal women

Breast Cancer Research and Treatment

Volumn 120, Issue 2, 2010, Pages 427-435

  Cigler, T ^a   Tu, D ^b   Yaffe, M J ^c   Findlay, B ^d   Verma, S ^e   Johnston, D ^b   Richardson, H ^b   Hu, H ^f   Qi, S ^f   Goss, P E ^f  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b National Cancer Institute of Canada Clinical Trials Group   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d Systeme de sante de Niagara   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Aromatase inhibitor; Bone biomarkers; Bone mineral density; Breast cancer; Clinical trial; Letrozole; Lipids; Mammographic breast density

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; ESTRADIOL; ESTRONE; ESTRONE SULFATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; COMPUTER ASSISTED RADIOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEASIBILITY STUDY; FEMALE; FEMUR NECK; HORMONE BLOOD LEVEL; HUMAN; IMAGE ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTICENTER STUDY; OSTEOLYSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; BONE DENSITY; BREAST; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; MAMMOGRAPHY; MIDDLE AGED; NITRILES; POSTMENOPAUSE; TRIAZOLES;

EID: 77950691631     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0662-0     Document Type: Article

References (47)

1. Boyd NF, Byng JW, Jong RA et al (1995) Quantitative classification of mammographic densities and breast cancer risk: results from, the Canadian National Breast Screening Study. J Natl Cancer Inst 87:670-675
2. Boyd NF, Guo H, Martin LJ et al (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356:227-236 (Pubitemid 46143226)
3. Boyd NF, Rommens JM, Vogt K et al (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798-808 (Pubitemid 41430721)
4. Byrne C, Schairer C, Brinton LA et al (2001) Effects of mam-mographic density and benign breast disease on breast cancer risk. (United States). Cancer Causes Control 12:103-110 (Pubitemid 32165267)
5. Byrne C, Schairer C, Wolfe J et al (1995) Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87:1622-1629
6. Harvey JA, Bovbjerg VE (2004) Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 230:29-41 (Pubitemid 37549780)
7. McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a metaanalysis. Cancer Epidemiol Biomarkers Prev 15:1159-1169
8. Ursin. G, Ma H, Wu AH et al (2003) Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 12:332-338 (Pubitemid 36427994)
9. Wolfe JN, Saftlas AF, Salane M (1987) Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. AJR Am J Roentgenol 148:1087-1092
10. Greendale GA, Reboussin BA, Sie A et al (1999) Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 130:262-269 (Pubitemid 29091853)
11. Knight JA, Martin LJ, Greenberg CV et al (1999) Macronutrient intake and change in mammographie density at menopause: results from a randomized trial. Cancer Epidemiol Biomarkers Prev 8:123-128
12. Cyrlak D, Wong CH (1993) Mammographic changes in postmenopausal women undergoing hormonal replacement therapy. AJR Am J Roentgenol 161:1177-1183 (Pubitemid 24008058)
13. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S (2001) Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 285:171-176 (Pubitemid 32048518)
14. Stomper PC, Van Voorhis BJ, Ravnikar VA, Meyer JE (1990) Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 174:487-490
15. Atkinson. C, Warren. R, Bingham. SA, Day NE (1,999) Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 8:863-866
16. Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J (2000) Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 9:911-915
17. Chow CK, Venzon D, Jones EC, Premkumar A, O'Shaughnessy J, Zujewski J (2000) Effect of tamoxifen on mammographic density, Cancer Epidemiol Biomarkers Prev 9:917-921
18. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW (2004) Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96:621-628 (Pubitemid 38584986)
19. Konez O, Goyal M, Reaven RE (2001) Can tamoxifen cause a significant mammographic density change in breast parenchyma? Clin Imaging 25:303-308
20. Son HJ, Oh KK (1999) Significance of follow-up mammography in estimating the effect of tamoxifen in breast cancer patients who have undergone surgery. AJR Am J Roentgenol 173:905-909
21. Ursin G, Pike MC, Spicer DV, Porrath SA, Reitherman RW (1996) Can mammographic densities predict effects of tamoxifen on the breast? J Natl Cancer Inst 88:128-129
22. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE (1995) In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer, Clin Cancer Res 1:1511-1515
23. Geisler J (2003) Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 86:245-253
24. Miller WR, Dixon JM (2001) Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 79:93-102
25. Jong R, Fishell E, Little L, Lockwood G, Boyd NF (1996) Mammographic signs of potential relevance to breast cancer risk: the agreement of radiologists' classification. Eur J Cancer Prev 5:281-286 (Pubitemid 26342141)
26. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ (1994) The quantitative analysis of mammographic densities. Phys Med Biol 39:1629-1638
27. Boyd NF, Greenberg C, Lockwood G et al (1997) Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst 89: 488-496
28. Stone J, Gunasekara A, Martin LJ, Yaffe M, Minkin S, Boyd NF (2003) The detection of change in mammographic density. Cancer Epidemiol Biomarkers Prev 12:625-630
29. Vachon CM, Ingle JN, Suman VJ et al (2007) Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. Breast 16:204-210
30. Noh JJ, Maskarinec G, Pagano I, Cheung LW, Stanczyk FZ (2006) Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women. Breast 15:20-28 (Pubitemid 43210545)
31. Aiello EJ, Tworoger SS, Yasui Y et al (2005) Associations among circulating sex hormones, insulin-like growth factor,lipids, and mammographic density in postmenopausal women. Cancer Epidemiol Biomarkers Prev 14:1411-1417 (Pubitemid 40807339)
32. Warren R, Skinner J, Sala E et al (2006) Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:1502-1508 (Pubitemid 44299323)
33. Verheus M, Peeters PH, van Noord PA, van der Schouw YT, Grobbee DE, van Gils CH (2007) No relationship between circulating levels of sex steroids and mammographic breast density: the Prospect-EPIC cohort. Breast Cancer Res 9:R53 (Pubitemid 350187470)
34. Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT (2007) Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. Int J Cancer 121:2506-2511 (Pubitemid 350022421)
35. Boyd NF, Stone J, Martin LJ et al (2002) The association of breast mitogens with mammographie densities. Br J Cancer 87:876-882 (Pubitemid 35252963)
36. Greendale GA, Palla SL, Ursin G et al (2005) The association of endogenous sex steroids and sex steroid binding proteins with mammographie density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 162:826-834 (Pubitemid 41541366)
37. Tamimi RM, Hankinson SE, Colditz GA, Byrne C (2005) Endogenous sex hormone levels and mammographie density among postmenopausal women, Cancer Epidemiol Biomarkers Prev 14:2641-2647 (Pubitemid 41752727)
38. Greendale GA, Huang MH, Ursin G et al (2007) Serum prolactin levels are positively associated with mammographie density in postmenopausal women. Breast Cancer Res Treat 105:337-346 (Pubitemid 47596443)
39. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE (2000) Plasma insulin-like growth factor (IGF) I, IGFbinding protein 3, and mammographie density. Cancer Res 60:3744-3748 (Pubitemid 30641913)
40. Diorio C, Pollak M, Byrne C et al (2005) Insulin-like growth factor-I, IGF-binding protein-3, and mammographie breast density. Cancer Epidemiol Biomarkers Prev 14:1065-1073
41. Maskarinec G, Williams AE, Kaaks R (2003) A. cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 107:991-996 (Pubitemid 37429842)
42. Bremnes Y, Ursin G, Bjurstam N, Rinaldi S, Kaaks R, Gram IT (2007) Insulin-like growth factor and mammographie density in postmenopausal Norwegian women. Cancer Epidemiol Biomarkers Prev 16:57-62 (Pubitemid 46174264)
43. Boyd NF, Connelly P, Byng J et al (1995) Plasma lipids, lipoproteins, and mammographie densities. Cancer Epidemiol Biomarkers Prev 4:727-733
44. Hong CC, Tang BK, Hammond GL, Tritchler D, Yaffe M, Boyd NF (2004) Cytochrome P450 1A2 (CYPl A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res 6:R352-R365
45. Perez EA, Josse RG, Pritchard KI et al (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA, 17. J Clin Oncol 24:3629-3635
46. Lonning PE, Geisler J, Krag LE et al (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126-5137 (Pubitemid 46224021)
47. Wasan KM, Goss PE, Pritchard PH et al (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA. 17L). Ann Oncol 16:707-715 (Pubitemid 40767090)